Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S G Gray

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Endocrine, Metabolic & Immune Disorders Drug Targets|March 12, 2009
Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disordersM W Lawless, S Norris, K J O'Byrne, et al.
Gene Expression|April 15, 2003
Modulation of splicing events in histone deacetylase 3 by various extracellular and signal transduction pathwaysS G Gray, A H Iglesias, B T Teh, et al.
The International Journal of Developmental Biology|August 26, 1998
Developmental-dependent DNA methylation of the IGF2 and H19 promoters is correlated to the promoter activities in human liver developmentX Li, S G Gray, F Flam, et al.
British Journal of Cancer|September 20, 2000
Comparative genomic hybridization reveals population-based genetic alterations in hepatoblastomasS G Gray, S Kytölä, T Matsunaga, et al.
Genomics|October 23, 1998
Human histone deacetylase 2, HDAC2 (Human RPD3), is localized to 6q21 by radiation hybrid mappingR Betz, S G Gray, C Ekström, et al.
International Journal of Molecular Medicine|December 22, 1999
Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinomaS G Gray, S Kytola, W O Lui, et al.
International Journal of Oncology|March 11, 2004
Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell linesS G Gray, C-N Qian, K Furge, et al.
Experimental Cell Research|December 10, 1999
IGF-II enhances trichostatin A-induced TGFbeta1 and p21(Waf1,Cip1, sdi1) expression in Hep3B cellsS G Gray, T Yakovleva, W Hartmann, et al.
International Journal of Oncology|September 20, 2001
Differential expression of class I HDACs: roles of cell density and cell cycleF Dangond, M Henriksson, G Zardo, et al.
Cytokine|July 6, 2000
IGF-II and IL-2 act synergistically to alter HDAC1 expression following treatments with trichostatin aS G Gray, I Svechnikova, W Hartmann, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Endocrine, Metabolic & Immune Disorders Drug Targets|March 12, 2009
Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disordersM W Lawless, S Norris, K J O'Byrne, et al.
Gene Expression|April 15, 2003
Modulation of splicing events in histone deacetylase 3 by various extracellular and signal transduction pathwaysS G Gray, A H Iglesias, B T Teh, et al.
The International Journal of Developmental Biology|August 26, 1998
Developmental-dependent DNA methylation of the IGF2 and H19 promoters is correlated to the promoter activities in human liver developmentX Li, S G Gray, F Flam, et al.
British Journal of Cancer|September 20, 2000
Comparative genomic hybridization reveals population-based genetic alterations in hepatoblastomasS G Gray, S Kytölä, T Matsunaga, et al.
Genomics|October 23, 1998
Human histone deacetylase 2, HDAC2 (Human RPD3), is localized to 6q21 by radiation hybrid mappingR Betz, S G Gray, C Ekström, et al.
International Journal of Molecular Medicine|December 22, 1999
Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinomaS G Gray, S Kytola, W O Lui, et al.
International Journal of Oncology|March 11, 2004
Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell linesS G Gray, C-N Qian, K Furge, et al.
Experimental Cell Research|December 10, 1999
IGF-II enhances trichostatin A-induced TGFbeta1 and p21(Waf1,Cip1, sdi1) expression in Hep3B cellsS G Gray, T Yakovleva, W Hartmann, et al.
International Journal of Oncology|September 20, 2001
Differential expression of class I HDACs: roles of cell density and cell cycleF Dangond, M Henriksson, G Zardo, et al.
Cytokine|July 6, 2000
IGF-II and IL-2 act synergistically to alter HDAC1 expression following treatments with trichostatin aS G Gray, I Svechnikova, W Hartmann, et al.
Pageof 3